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ess: siafak@med.uoc.grSummary CD8+ve T-cell responses play a primary role in chronic obstructive
pulmonary disease (COPD), but there is little information regarding COPD
exacerbations. Sputum induction is a relatively non-invasive and safe method to
study airway inflammation. The aim of the study was to investigate changes in
airway T-lymphocyte subpopulations at the onset of severe COPD exacerbations via
analysis of sputum. Induced sputum samples were collected from 12 COPD patients
aged (mean7SD) 6977 years, ex-smokers (68723 pack-years), mean FEV1 (%pre-
dicted) 40714 at the onset of an acute severe exacerbation requiring hospital
admission and 16 weeks after remission of the exacerbation. Inflammatory cells and
T-lymphocyte subpopulations (CD4, CD8, Tc1, Tc2) were measured using chemical
and double immunocytochemical methods. Increased percentages of sputum
neutrophils (P ¼ 0:002) and decreased CD4/CD8 and CD8-IFNg/CD8-IL4+ve (Tc1/
Tc2) cell ratios (P ¼ 0:03;P ¼ 0:02; respectively) were found at the onset of
exacerbation compared to stable state. We conclude that a CD8+ve type-2-mediated
immune response is induced at the onset of severe COPD exacerbation.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
0 392433;
(N.M. Siafakas).Introduction
Chronic obstructive pulmonary disease (COPD) is a
disease state characterized by airflow limitation,
associated with an abnormal inflammatory re-
sponse of the lungs to noxious particles or gases,
specifically cigarette smoke.1 Scientific evidenceed.
ARTICLE IN PRESS
T-cells on COPD exacerbation 573supports a primary role for CD8+ve T-cell-mediated
immunity in the development of inflammation in
COPD. Increased CD8+ve T-lymphocyte numbers
have been found in the airways and lung parench-
yma of COPD patients in comparison to ‘‘healthy
smokers’’ and healthy non-smokers.2–5 Moreover, a
strong correlation has been found between severity
of airflow limitation and the number of CD8+ve
cells in bronchoalveolar lavage fluid (BALF), sputum
and biopsies from COPD patients.2–6 CD8+ve cells
are mainly divided into three subpopulations,
depending on their cytokine profile.7 Type-1 cells
(Tc1) produce interferon g (IFNg), type-2 cells (Tc2)
produce interleukin 4(IL4), while type-0 (Tc0) cells
produce both cytokines. Both Tc1 and Tc2 cells
show comparable cytotoxicity.8 Which subpopula-
tion of CD8+ve lymphocytes is mostly involved in
COPD pathogenesis is currently under investigation.
Some first evidence coming from blood and lung
biopsy studies supports the predominance of type-1
T-cells.9,10
COPD is a continuously deteriorating disease with
periodic exacerbations and remissions. Patients
suffering from a severe COPD exacerbation often
require hospitalization. Hospital mortality of pa-
tients admitted for an acute exacerbation of COPD
is approximately 10% and the long-term outcome is
poor.1 Although increased inflammation has been
presumably related to COPD exacerbations, there
has been little information available on the type of
inflammation at the onset of severe COPD exacer-
bations.11–20 This may be partly due to technical
difficulties in studying such seriously diseased
patients. Common methods to study inflammation
on stable COPD patients, such as the examination
of BALF, bronchial biopsies or surgical specimens,
cannot be easily applied on the case of exacerba-
tion. Sputum induction has been proven a safe,
reliable and highly reproducible technique, which
could be used for the analysis of inflammatory cell
profiles on COPD exacerbations by ethically allow-
ing further samples to be taken when patients are
stable.21
So far evidence suggests that sputum and tissue
eosinophil numbers are increased during mild
exacerbations, while tissue neutrophil numbers
and neutrophilic markers during severe exacerba-
tions.11,12,16,20 Although high tissue CD8+ve T-
lymphocyte numbers have been reported in stable
patients with COPD, there is no information
regarding changes in T-lymphocyte populations
and subpopulations on severe COPD exacerbations.
Considering that infections are the most frequent
cause of an exacerbation and infections trigger a T-
cell-mediated immune response, we wished to test
the hypothesis that an increase in sputum CD8+ cellnumbers and a change in T-lymphocyte phenotypes
occurs at the onset of severe COPD exacerba-
tions.22 Furthermore, we wished to investigate
whether there are any changes in neutrophil or
eosinophil numbers associated with severe COPD
exacerbations. For this reason we analyzed sputum
inflammatory populations, including T-lymphocyte
subpopulations, at the onset of a severe COPD
exacerbation requiring hospital admission and on
stable condition. Our results showed a statistically
significant increase in sputum neutrophil percen-
tages and decrease in CD4/CD8 and CD8-IFNg/CD8-
IL4+ve cell ratios on severe exacerbation relative to
stable state, suggesting that a CD8+ve type-2-
mediated immune response was induced at the
time of the exacerbation.Material and methods
Study subjects
Twelve patients with COPD were studied at the
onset of an acute severe exacerbation and on
stable condition. Diagnosis of COPD was made
according to the GOLD criteria.1 In order to enter
the study, the patient had to have satisfied the
following inclusion criteria: (1) an ex-smoking
history of at least 20 pack-years of smoking (2)
fixed airflow limitation with salbutamol reversibil-
ity of o12% or o200ml. Exclusion criteria in-
cluded: (1) a history of allergy; (2) current smoking
or history of having smoked within 2 years of
assessment; (3) use of other medication than
inhaled b2 agonists, anti-cholinergics and inhaled
steroids; (4) history of a concomitant pulmonary or
systemic disease that could predispose to severe
exacerbations (e.g. bronchiectasis, heart failure);
(5) long-term oxygen therapy.Study design
Recruitment of COPD patients was made from those
admitted for a severe COPD exacerbation in the
Department of Thoracic Medicine in the University
Hospital of Heraklion. Exacerbation was defined as
severe if the patient fulfilled one of the following
criteria: use of accessory respiratory muscles,
paradoxical chest wall movements, respiratory
failure breathing room air, requiring hospital
admission. Between January and June 2002, a total
of 156 admissions were recorded. Fourteen patients
satisfied the inclusion and exclusion criteria and
were enrolled in the study. All patients were under
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enrollment.
Induced sputum samples were taken at the
emergency room, where the patients referred for
the treatment of the first signs of a severe
exacerbation, before any therapeutic intervention
was done. A chest radiograph and blood gases
analysis was done. All patients were treated with
systemic steroids until remission of the exacerba-
tion and with inhaled steroids after remission of the
exacerbation. No change in any of the patients
regular medication was introduced after recovery
from the exacerbation. Twelve out of the 14
patients were reassessed on a scheduled visit 16
weeks after remission of the exacerbation. Two
patients were excluded from the study because
they experienced another exacerbation and/or an
acute respiratory tract infection within the 16
weeks period. Induced sputum samples were
collected again at stable condition; spirometry,
skin-prick reaction tests and blood gases analysis
were also performed.
Induced sputum from exacerbation and stable
state of the same patient was processed for
analysis of inflammatory cells and T-lymphocyte
subsets and sent to the microbiology department
for detection of common microorganisms (gram
stain and bacterial cultures for aerobes and anae-
robes). An acute bacterial infection on exacerba-
tion was defined as demonstration of a new
pathogenic organism cultured from sputum on the
day of exacerbation, but not cultured at baseline.
The Ethical Committee of the University Hospital
of Heraklion in Crete, Greece, approved the
protocol and all subjects gave their written con-
sent.Methods
Sputum induction and processing
Sputum was induced and processed based on the
method of Pin et al.,23,24 as previously described.
Lymphocytes were stimulated by incubating the
cell suspension in 24-well plates at a concentration
of 2 103 cells/ml for 5 h, under 5% CO2, at 37 1C, in
RPMI-1640 at 10% FCS (Invitrogen Corporation
Carlsbad, California, USA) in the presence of
phorbol 12-myristate 13-acetate 25 ng/ml, ionomy-
cin 1 mmol/L and brebeldin A 10 mg/ml (Sigma ST
Louis, Missouri, USA). Cytospins were made using
cytocentrifugation of 50 ml of a 3.5 103 cells/ml
cell suspension and were stored at 80 1C for
immunocytochemical analysis later. Approximately
175,000 cells were cytospined on each slide, amongwhich there were sufficient number of lymphocytes
to stain.Immunocytochemical analysis
After defrosting the cytospins they were fixed in
acetone and rehydrated in TBS. The double im-
munocytochemical method was performed as pre-
viously described.21 Two investigators examined the
slides under double visual and ultraviolet micro-
scope and their results were averaged. The be-
tween-observer coefficient of variation was o15%.
The visual filter was used to differentiate cells by
morphology and the UV filter to count fluorescent
lymphocytes in the same optical field. Three
replicate measurements were performed by each
observer in 10 slides. The within observer repeat-
ability was tested using agreement analysis and the
K coefficient was always 40.8. Results were
expressed as ratio of CD4+ve to CD8+ve cells and
of CD8+ve-IFNg producing T-cells to CD8+ve-IL4
producing T-cells. For the estimation of each ratio
500 T-cells were counted for each patient, with
more than one cytospin stained if necessary,
because this number was sufficient to obtain a mean
value per subject that remained constant after
further increasing the number of cells counted.
Measurement of CD4+ ve and CD8+ ve T-cells:
The primary anti-CD4 mouse anti-human monoclo-
nal antibody (Caltag Burlingame, CA, USA) with
secondary rabbit anti-mouse IgG-FITC antibody
(Immunotech Marseillle, France) and the primary
anti-CD8 mouse anti-human monoclonal antibody
(Caltag) with secondary rabbit anti-mouse IgG-
phycoerythrin-conjugated (IgG-PE) antibody (Im-
munotech) were used. Five hundred CD4+ve and
CD8+ve cells were counted to estimate CD4/CD8
ratio.
Measurement of CD8+ve-IFNg producing and
CD8+ve-IL4 producing T-cells: The primary anti-
CD8 mouse anti-human monoclonal antibody with
secondary rabbit anti-mouse IgG-FITC antibody and
the primary anti-IFNg mouse anti-human monoclo-
nal antibody (Caltag) with secondary rabbit anti-
mouse IgG-phycoerythrin-conjugated (IgG-PE) anti-
body were used. Five hundred CD8+ve cells were
counted to estimate the number of CD8-IFNg+ve
cells. The same method was applied for staining
CD8+ve cells with anti-IL4 antibody (Caltag).Statistical analysis
Data are presented as mean7SD for normally and as
median (range) for non-normally distributed vari-
ables. Differences between stable state and ex-
acerbation state were tested using the Wilcoxon
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test for normally distributed variables. Normality
was tested by the Shapiro–Wilk test. The statistical
software StatsDirect (Camcode Cambridge, UK) was
used for the entire analysis. A P-value ofo0.05 was
considered statistically significant.
Due to significant comorbidities in the majority
of COPD patients admitted for severe exacerbation,
we were only able to recruit a relatively limited
number of patients. The significant differences of
all variables compared were evaluated against the
criterion, alpha. According to the data and the
results of the study: (a) number of patients (sample
size), (b) differences obtained for all variables
tested (effect size) and, (c) criterion a ¼ 0:05 the
power was always greater than 80%. Therefore, it is
unlikely that a type 1 error has occurred.Results
Subjects
Demographic data, baseline and exacerbation
characteristics of all subjects are given in Table 1.
All had negative skin-prick reaction tests and serum
IgE levels within normal range. All patients re-
ceived the same medication at the onset of the
exacerbation and on stable state. No subject was
able to perform acceptable spirometry at the onset
of the exacerbation. A clear deterioration in cough,
sputum and blood gases analysis was observed in allTable 1 Democraphic data of the subjects on stable sta
Male 11
Female 1
Age 6977 yr
Smoking history 68723 p/yr
Inh steroid intake 500 (500–10
Stable
FEV1 (%pred) 40714
FEV1/FVC (%pred) 53711
DFEV1 (%baseline) 4(4,9)
PO2 72711
PCO2 3975
Purulent sputum 0/12
Positive sputum cultures 0/12
Cough 4/12
Dyspnea at rest 3/12
Data are presented as mean7SD for normally and as median (ran
Abbreviations: p/yrs: pack/years, Inh: inhaled, fl: flouticasone, a
*Po0:05:
ySubjects were not able to perform proper spirometric test atsubjects on exacerbation. All had a PO2o60mmHg
at the time of the exacerbation. Five patients had
positive sputum cultures at the onset of exacerba-
tion (three for S. pneumoniae and two for Ps.
aeroginosa). Chest radiographs at the time of
exacerbation did not reveal pneumonia or pneu-
mothorax in any patient.
Cellular composition
Viability of cells recovered by sputum processing
was 89(59–99)% median (range) and 89(63–98)% on
exacerbation and on stable state, respectively. The
percentage of squamous epithelial cells among
total cells was 0.2(0.04–1)% on exacerbation and
1.3(0.1–4.7%) on stable conditions. No statistically
significant difference was observed in cell viability
or squamous cell contamination between exacer-
bation samples and stable state samples. Table 2
shows sputum cellularity in both states. Percen-
tages of neutrophils were significantly higher on
exacerbation (P ¼ 0:002). In contrast, percentages
of macrophages were significantly lower at the
onset of exacerbation (P ¼ 0:003). No statistically
significant difference was observed in percentages
of eosinophils, lymphocytes or total non-squamous
cell count between exacerbation and stable state.
A lower CD4/CD8+ve cell ratio (P ¼ 0:03) and a
lower CD8-IFNg/CD8-IL4+ve cell ratio (P ¼ 0:02) were
found at the onset of exacerbation (Figs. 1 and 2).
No difference was observed in any of the above cell
counts or ratios between subjects with bacterial +ve
or ve cultures at the onset of exacerbation.te and at the onset of exacerbation.
00)mgfl or 400(400–600)mg bd
Exacerbation
y
y
y
5177*
5378*
6/12
5/12
9/12
12/12
ge) for non-normally distributed variables.
nd bd: budesonide.
the onset of severe exacerbation.
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Table 2 Total non-squamous cell count ( 106 cells/gr sputum), percentages of neutrophils, lymphocytes,
macrophages and eosinophils (% in non-squamous cells) in the same COPD patients on stable state (SS) and at the
onset of severe exacerbation (ES).
NEU%* LYM% MAC%* EOS% TCC 106
SS ES SS ES SS ES SS ES SS ES
1 98 99 1 0.5 1 0.5 0 0 42 31
2 81 98 1 1 18 1 0 0 8 69
3 55.5 89.5 2 1 42 8 0.5 1.5 24 36
4 85 98 1 1 14 1 0 0 23 15
5 79 98 1 1 19 1 1 0 11 55
6 69 93 2 1 29 6 0 0 65 28
7 97 98 1 1 1 1 1 0 6 65
8 90 98 1 1 9 1 0 0 10 40
9 88 94 1 1 9 5 2 0 77 100
10 82 99 1 0.1 13 0.9 4 0 20 6
11 82 97 2 2 15 1 1 0 29 44
12 85 93 2 1 13 5 0 1 32 35
Abbreviations: TCC: total non-squamous cell count, NEU: neutrophils, LYM: lymphocytes, MAC: macrophages, EOS: eosinophils,
ES: severe exacerbation, and SS: stable state. ADDIN
*Po0:05:
0.75
1.00
1.25
1.50
1.75
2.00
ExacerbationStable state
p=0.03
CD
4/
CD
8 
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Figure 1 CD4/CD8+ve cell ratios in sputum samples from
the same COPD patients on stable state and at the onset
of severe exacerbation.
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Figure 2 CD8-INFg/CD8-IL4+ve cell ratios in sputum
samples from the same COPD patients on stable state
and at the onset of severe exacerbation.
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Although T-cell-mediated immunity has been asso-
ciated with stable COPD, relatively little is known
about the role of T-cells in severe exacerbations.
This study examined changes in airway T-lympho-
cyte subpopulations at the onset of severe COPDexacerbations requiring hospital admission. Our
results showed decreased CD4/CD8 and CD8-IFNg/
CD8-IL4+ve cell ratios on exacerbation relative to
clinically stable condition. This evidence suggests
that an imbalance in T-lymphocyte subpopulations
might be associated with the development of
severe COPD exacerbations.
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by immunocytochemical methods. Although the
number of T-lymphocytes in sputum relative to
other biological materials is low, by using a highly
concentrated sample of sputum cells on the
preparations of our slides, we achieved to get a
good number of lymphocytes. Before immunocyto-
chemistry T-lymphocytes were stimulated with PMA
and ionomycin. Although after differentiation into
Tc1 and Tc2 subtypes, T-lymphocytes show a stable
cytokine pattern and rarely, if ever, switch to the
opposite phenotype, this intervention might have
altered the cytokine profile of the cells.8 However,
differences found in T-cell subsets in vitro must
represent real differences in vivo, since all samples
were stimulated in the same way.
Considering important to achieve high repeat-
ability of our results, we tried as much as possible
to eliminate variability in sputum sampling. A
standard saline concentration was always used
(N/S) for all patients. Moreover, all sputum induc-
tion and processing were performed from the same
investigator. By using a relatively high cell count
per slide and by minimizing variability in sputum
sampling, we achieved good agreement in the
analysis of different sputum aliquots. Ten different
slides from the same sputum sample of 5 patients
were stained for T-lymphocyte subpopulations and
counted. Intra-sample coefficient of variation was
o7%. Repeatability of our results within interval of
2 days was tested and found to be 490% in the
same patient.24
Previous studies in patients with COPD have
shown increased tissue CD8+ve T-lymphocytes and
a close correlation between the number of theses
cells and severity of airflow limitation.2–4 We have
recently shown that COPD patients demonstrate
decreased sputum CD4/CD8+ve cell ratios and
increased CD8+ve cell perforin expression and
cytotoxic activity relative to ‘‘healthy smo-
kers’’.6,25 However, the exact role of CD8+ve cells
in the pathophysiology of COPD is not yet fully
understood. Interesting evidence suggests that
they can cause a TNF-a-mediated lung injury.26
Saetta et al.3,4 have suggested that an excessive
recruitment of CD8+ve T-lymphocytes may occur in
response to repeated viral infections in some
smokers, and that this excessive response may
damage the lungs of these subjects.
Our results showed similar sputum lymphocyte
counts between exacerbation and stable state, but
significantly decreased CD4/CD8+ve cell ratios at
the onset of severe COPD exacerbation requiring
hospital admission (P ¼ 0:03) (Fig. 1). Therefore, a
further shift towards the CD8+ve cell-mediated
immune response was seen on severe COPDexacerbation. Such a response may have been
induced by viral or bacterial respiratory tract
infections, which are thought to be the most
common triggers of acute COPD exacerbations.22
Indeed, 6 patients presented with purulent sputum
at the onset of the exacerbation and 5 out of these
6 had positive cultures on exacerbation and
negative on stable state (Table 1).
No difference was observed in CD4/CD8+ve cell
ratios between patients with bacterial +ve or ve
exacerbation. Although the relatively limited num-
ber of patients included in the present study does
not allow us to make safe conclusions, a plausible
explanation is that viral infections triggered the
CD8+ve response in patients with bacterial ve
exacerbations.
Despite the statistically significant difference in
CD4/CD8+ve cell ratio between exacerbation and
stable state, 4 patients showed either no change or
slight increase in their ratio (Fig. 1). This phenom-
enon was observed irrespective of the presence of
bacterial positive sputum cultures on exacerbation.
COPD patients presenting with decreased CD4/
CD8+ve cell ratio on exacerbation could represent
an interesting phenotype related to accelerated
airway inflammation and disease deterioration. On
the other hand, some patients may not increase
their CD8+ve cell numbers on exacerbation due to
an already maximal increase in the CD8+ve re-
sponse under stable conditions or because the
triggering factor of their exacerbation is other
than respiratory tract infection. Either hypothesis
needs to be further investigated for any conclusions
to be made safely.
Saetta et al.11 have shown increased CD3+ (T-
cell) numbers in endobronchial biopsies from COPD
patients on mild exacerbations, but no difference
in CD4 or CD8+cell numbers. This seems to come in
contrast to our findings of decreased CD4/CD8+ve
cell ratios at the onset of severe COPD exacerba-
tion. However, it is not safe to make comparisons
between ratios and absolute numbers. Moreover,
different results could be attributed to the fact
that we have studied severe COPD patients on
severe exacerbations or that we have examined
sputum samples and not endobronchial biopsies.
We have gone further in evaluating this increase
in CD8+ve T-lymphocytes and found significantly
decreased CD8-IFNg/CD8-IL4+ve cell ratios in COPD
patients on severe exacerbation, irrespective of
the presence of bacterial positive sputum cultures
on exacerbation (P ¼ 0:02) (Fig. 2). Since Tc0 cells
are IFNg as well as IL4+ve, lower CD8-IFNg/CD8-
IL4+ve cell ratio means lower Tc1/Tc2 ratio. There-
fore, the Tc2-type reaction is enhanced on severe
COPD exacerbations. Saetta et al.9,10 reports high
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patients when compared to healthy smokers or to
non-smokers, while a type-1 cytokine phenotype
has been also demonstrated in peripheral blood.
The switch towards the Tc2 phenotype on acute
severe exacerbations of COPD may be implicated in
the inflammatory processes of severe exacerba-
tions. Tc2 cells do not produce INFg and reduced
ability of producing INFg prevents the elimination
of pathogens.27,28 Reduced anti-viral activity of Tc2
cells in vivo may not always be due to INFg
secretion but to decreased expression or lower
activity of adhesion molecules.29 Furthermore, Tc2
cells produce IL4, which down-regulates some steps
of cell-mediated responses that are required for
host protection.27,28 Therefore, an increase in Tc2
cells could lead to severe respiratory tract infec-
tion and therefore severe COPD exacerbation.
Although the overall difference between exacer-
bation and stable state was statistically significant,
4 patients showed almost no change in their sputum
CD8-INFg/CD8-IL4+ve cell ratio between exacerba-
tion and stable state. This was not related to the
presence of bacterial positive sputum cultures on
exacerbation. Among those patients, 2 had also
shown no change in CD4/CD8+ve cell ratio.
Obviously, changes in lymphocyte subpopulations
do not occur in all COPD patients at the onset of
acute exacerbation, which supports the hypothesis
of more than one phenotypic reaction on acute
COPD exacerbation. Should this hypothesis be
confirmed, it would be of interest to investigate
the natural history of different exacerbation
phenotypes.
Increased percentages of sputum neutrophils
were demonstrated at the onset of bacterial +ve
or ve COPD exacerbations requiring hospital
admission. Saetta et al.11 and Qiu et al.20 have
reported a similar increase in neutrophil numbers in
endobronchial biopsies taken from COPD patients
on mild or severe exacerbation, respectively.
Furthermore, the neutrophil chemoattractants
CXCL8, CXCR1, CXCL5 and CXCR2 appear to play
important roles in the airway neutrophilia char-
acteristic of severe exacerbations. Taken together,
these results and ours provide convincing evidence
that neutrophils are implicated in the pathogenesis
of COPD exacerbations. Neutrophils could be
involved in the pathology of COPD exacerbations
through the release of proteolytic enzymes and
reactive oxygen species.30
Aaron et al.18 showed that COPD patients exhibit
prominent sputum neutrophilia during acute ex-
acerbations, independent of a demonstrable viral
or bacterial airway infection. On the contrary, Sethi
et al.15 demonstrated increased airway inflamma-tion in patients with H. infuenza and M. catarhalis
exacerbations when compared to H. parainfluenza
and bacterial ve exacerbations. It could be
possible that Aaron et al. and we did not find a
correlation between airway inflammation and
bacterial +ve exacerbations due to the small
number of patients included in both studies.
On contrary to neutrophils, no difference was
found in sputum eosinophil percentages or numbers
between severe COPD exacerbation and stable
state. These results confirm previous evidence that
eosinophils are involved in mild exacerbations,
while neutrophils in severe COPD exacerba-
tions.11,12,16,20
In conclusion, COPD patients at the beginning of
their hospitalization for a severe exacerbation
demonstrated increased sputum neutrophil percen-
tages and decreased CD4/CD8 and Tc1/Tc2 ratios.
These findings suggest that a CD8+ve type-2
exacerbation phenotype may be associated with
increasing severity of COPD exacerbations and
indicate future therapeutic strategies aimed at
regulating CD8+ve type-2-mediated immune re-
sponses on severe COPD exacerbations. However,
further studies are needed before phenotypes of T-
cell-mediated immune responses at the onset of
acute exacerbations of COPD are well defined.References
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